In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company’s mission, and the challenges ahead.
Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 15 October 2021 and 21 October 2021 the Company issued 3,904,910 fully paid ordinary
The document “Application for quotation of +securities” was lodged with ASX on 21 October, 2021. Please click to review the full announcement at ASX.
The document “Notice to IBXO Option Holders” was lodged with ASX on 14 October, 2021. Please click to review the full announcement on ASX.
The document “Application for quotation of +securities” was lodged on 12 October 2021. Please click to review the full announcement at ASX.
A Cleansing Notice under Section 708A was lodged at ASX on 12 October 2021. Please click to review the full announcement at ASX.
The document “Application for quotation of +securities” was lodged at ASX on 30th September 2021. Please click to review the full announcement at ASX.
A Cleansing Notice under Section 708A was lodged with ASX on 30th September, 2021. Please click to review the full announcement at ASX.
The document “Notification of cessation of +securities” was lodged at ASX on 16 September, 2021. Please click to review the full announcement at ASX.
The document “Application for quotation of +securities” was lodged with ASX on 16 September, 2021. Please click to review the full announcement at ASX.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance